Beta Bionics Raises 2026 Guidance to 37–39% Growth, Adds 20 Sales Territories
Beta Bionics raised its new patient starts guidance to 37–39% growth driven by high 30%+ pharmacy channel adoption and expects a seasonal Q2 uptick. The company plans to add at least 20 new sales territories in 2026 while reporting a one-time gross margin tailwind in Q1.
1. Guidance and Pharmacy Channel Growth
Management updated its new patient starts growth guidance to 37–39%, noting consistent high 30%+ adoption through the pharmacy channel. They expect Q2 to deliver the largest seasonal step change after Q1, which historically is the weakest quarter for new starts.
2. Sales Force Expansion Plans
Beta Bionics aims to establish at least 20 additional sales territories in 2026, with the majority of hires and deployments occurring in Q1 and supplemental expansions in Q2. This ramp-up is positioned to support broader market coverage and accelerate future patient acquisition.
3. Gross Margin and Production Factors
Q1 gross margin benefited from one-time tailwinds related to increased iLet production, though these effects were described as relatively small. Management cautioned that such margin boosts can be unpredictable as the business faces potential one-time charges in any quarter.
4. Type 2 Adoption and Competitive Landscape
Approximately 25–30% of new users in Q1 had type 2 diabetes, despite the lack of a formal type 2 indication. Competitive moves—including a recent IPO and a nationwide pump launch—have had minimal impact, as the company focuses on differentiating its automated insulin delivery system.